Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB

blonca9
1 minute ago
1 min read

Chief Executive Officer Jack O'Meara, who previously founded Ochre Bio in the RNA space, describes the potential benefits of using brain shuttles and why the time is right for this approach. Plus, the company's business model and what to expect next.

Recent Posts

See All

Enanta Pharmaceuticals' CEO and CMO discuss data announced today on the company's RSV treatment, Zelicapavir, and describe the road ahead for this program and the company

Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.

Xspray Pharma makes protein kinase inhibitors that are amorphous, and therefore more soluble than current products. Dasynoc, its version of dasatinib (Sprycel), is in front of FDA with an Oct 7 PDUFA

Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies across the BBB

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight